Osteoporosis Screening: Dual-Energy X-ray Absorptiometry (DEXA), FRAX Scoring, and Antiresorptive Therapies
Key Clinical Takeaways
- Osteoporosis is a systemic skeletal disease characterized by low bone mineral density and microarchitectural deterioration predisposing to fragility fractures.
- Dual-Energy X-ray Absorptiometry (DEXA) of the femoral neck and lumbar spine is the gold standard diagnostic tool.
- A T-score of ≤ -2.5 defines Osteoporosis; a T-score between -1.0 and -2.5 defines Osteopenia (low bone mass).
- The WHO FRAX algorithm calculates 10-year probability of major osteoporotic fracture, guiding pharmacological treatment in osteopenia.
- Antiresorptive agents (bisphosphonates, denosumab) suppress osteoclastic resorption; anabolic agents (teriparatide, romosozumab) stimulate new bone formation.
Emergency Clinical Warning
Sudden onset of severe, incapacitating mid-back pain following minimal exertion (bending over or coughing) in an older adult signals an acute osteoporotic vertebral compression fracture.
Bone Remodeling Dynamics and Osteoporotic Pathophysiology
Bone is a dynamic, metabolically active connective tissue that undergoes continuous, lifelong cellular remodeling through the coupled actions of bone-resorbing osteoclasts and bone-forming osteoblasts. Under normal homeostatic conditions, osteoclasts excavate microscopic resorption pits on trabecular and cortical bone surfaces, which are subsequently refilled with mineralized osteoid matrix by osteoblasts.
Osteoporosis develops when the delicate equilibrium shifts toward uncoupled, excessive bone resorption: - Postmenopausal Osteoporosis: The abrupt cessation of ovarian estrogen synthesis at menopause accelerates bone loss. Estrogen normally suppresses osteoclastogenesis by downregulating the receptor activator of nuclear factor-κB ligand (RANKL) and upregulating osteoprotegerin (OPG). Estrogen deficiency unleashes high RANKL signaling, causing rapid, uncontrolled osteoclastic destruction of trabecular architecture. - Age-Related (Senile) Osteoporosis: Gradual decline in osteoblast synthetic capacity, blunted calcium absorption from vitamin D deficiency, and secondary hyperparathyroidism cause progressive thinning of cortical bone and increased skeletal fragility, predisposing individuals to low-trauma 'fragility fractures' (fractures resulting from a fall from standing height or less).
Diagnostic Evaluation: Dual-Energy X-ray Absorptiometry (DEXA)
Dual-Energy X-ray Absorptiometry (DEXA) is the diagnostic benchmark recommended by the USPSTF and the National Osteoporosis Foundation (NOF) for all women aged ≥65, men aged ≥70, and younger adults with clinical risk factors (e.g., chronic systemic corticosteroid therapy, rheumatoid arthritis, malabsorption).
DEXA utilizes two X-ray beams of differing energy levels to subtract soft tissue attenuation and precisely measure Bone Mineral Density (BMD in g/cm²) at central anatomical sites: the lumbar spine (L1-L4) and the hip (femoral neck and total hip). Results are reported as standardized statistical scores: - T-Score: Compares the patient's BMD to the mean peak bone density of a healthy 30-year-old reference population of the same sex: - Normal: T-score ≥ -1.0 SD. - Osteopenia (Low Bone Mass): T-score between -1.0 and -2.5 SD. - Osteoporosis: T-score ≤ -2.5 SD at any measured site. - Severe Osteoporosis: T-score ≤ -2.5 SD accompanied by a documented fragility fracture. - Z-Score: Compares BMD to an age- and sex-matched cohort. A Z-score ≤ -2.0 warrants comprehensive workup for secondary osteoporosis (hyperparathyroidism, multiple myeloma, Cushing's syndrome, celiac disease).
The WHO FRAX Algorithm: Treating Osteopenia
The majority of fragility fractures in the population actually occur in individuals categorized as having Osteopenia (T-score between -1.0 and -2.5), simply because this group is vastly larger than the osteoporotic cohort. Deciding which patients with osteopenia warrant prescription bone-strengthening medication is governed by the Fracture Risk Assessment Tool (FRAX)—a validated computer algorithm developed by the World Health Organization.
FRAX integrates femoral neck BMD alongside clinical risk factors: age, sex, BMI, prior personal fragility fracture, parental history of fractured hip, current cigarette smoking, systemic glucocorticoid use (≥5 mg prednisone daily for >3 months), rheumatoid arthritis, secondary osteoporosis, and heavy alcohol intake (≥3 units/day). Treatment Intervention Thresholds: Pharmacological anti-fracture therapy is indicated if the 10-year probability of a Major Osteoporotic Fracture (clinical spine, hip, forearm, or humerus) is ≥20%, OR if the 10-year probability of a Hip Fracture is ≥3.0%.
Therapeutic Classes: Antiresorptive vs. Anabolic Bone Formation
Contemporary medical management divides into two primary mechanistic classes:
1. Antiresorptive Therapeutics: - Bisphosphonates (Oral Alendronate 70 mg weekly, Risedronate; Intravenous Zoledronic Acid 5 mg yearly): Ingested bisphosphonates bind with high affinity to hydroxyapatite crystals on bone surfaces. During osteoclastic bone resorption, osteoclasts engulf the drug, which inhibits farnesyl pyrophosphate synthase, inducing osteoclast apoptosis and halting bone resorption. Patients taking oral bisphosphonates must take them with 8 oz of plain water upon waking and remain upright for 30 minutes to avert pill-induced chemical esophagitis. - Denosumab (Prolia): Fully human monoclonal antibody administered as a subcutaneous injection every 6 months that directly neutralizes RANKL, preventing osteoclast maturation. Crucial warning: Denosumab must never be delayed or abruptly stopped without bridging therapy, as stopping triggers rebound osteoclast activation and rapid vertebral fractures. 2. Anabolic Bone-Forming Agents: - Parathyroid Hormone Analogues (Teriparatide, Abaloparatide): Daily subcutaneous injections that stimulate osteoblastic new bone formation, reserved for severe osteoporosis (T-score < -3.0 or multiple fractures). - Romosozumab (Evenity): Dual-action monoclonal antibody blocking Sclerostin—simultaneously stimulating bone formation while suppressing bone resorption.
World Health Organization (WHO) Diagnostic Criteria for Osteoporosis via DEXA
| Diagnostic Category | DEXA T-Score Threshold | Fracture Risk Level | Standard Clinical Action |
|---|---|---|---|
| Normal Bone Mineral Density | T-score ≥ -1.0 SD | Baseline population risk | Calcium 1,000-1,200 mg/day, Vitamin D3 800-1,000 IU, weight-bearing exercise |
| Osteopenia (Low Bone Mass) | -1.0 < T-score < -2.5 SD | Mild-to-moderate elevation | Calculate WHO FRAX score; treat if Hip ≥3% or Major Fracture ≥20% |
| Osteoporosis | T-score ≤ -2.5 SD (Femur/Spine) | High (4x elevated fracture risk) | Initiate first-line antiresorptive therapy (Alendronate / Zoledronic acid) |
| Severe (Established) Osteoporosis | T-score ≤ -2.5 SD + Fragility Fracture | Extremely High | Consider first-line anabolic bone builder (Teriparatide / Romosozumab) |
Frequently Asked Clinical Questions
Peer-Reviewed Clinical References & Guidelines
- Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis - 2020 Update. Endocr Pract. 2020;26(Suppl 1):1-46.
- Kanis JA, Johnell O, Oden A, et al. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008;19(4):385-397.
- Saag KG, Petersen J, Brandi ML, et al. Romosozumab or Alendronate for Fracture Prevention in Postmenopausal Women. N Engl J Med. 2017;377(15):1417-1427.